EAM
PTGX icon

EFG Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

EFG Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$5.49M Buy
82,639
+913
+1% +$51.9K 0.71% 42
2025
Q2 		$4.52M Buy
81,726
+10,592
+15% +$508K 0.64% 60
2025
Q1 		$3.44M Buy
+71,134
New +$2.98M 0.57% 56

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

EFG Asset Management's PTGX Position: Q3 2025 in Review

EFG Asset Management increased its Protagonist Therapeutics (PTGX) stake by 1.1% in Q3 2025, buying an estimated $51.9K and bringing the position to 82,639 shares worth $5.49M. The position accounts for 0.71% of the portfolio, ranked #42.

EFG Asset Management first reported a position in PTGX in Q1 2025 and has held it in 3 quarters since. 274 funds tracked by Wall St. Rank hold PTGX as of Q3 2025.

  • EFG Asset Management held 82,639 shares of Protagonist Therapeutics worth $5.49M as of Q3 2025.
  • EFG Asset Management bought 913 Protagonist Therapeutics shares in Q3 2025, an estimated $51.9K.
  • Protagonist Therapeutics made up 0.71% of EFG Asset Management's portfolio in Q3 2025, its #42 holding.
  • EFG Asset Management first reported a position in Protagonist Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 274 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2025.

Based on EFG Asset Management's 13F filing for Q3 2025, filed 3 Nov 2025.